BRISTOL-MYERS SQUIBB$32.99
| Last Trade: |
32.99 |
| Trade Time: |
May 24 4:00 PM Eastern Daylight Time |
| Change: |
0.00 (0.00 %) |
| Prev Close: |
32.99 |
| Open: |
0.00 |
| Bid: |
31.06 |
| Ask: |
34.70 |
Quotes displayed are delayed by 15 minutes. Market data is provided by Telvent DTN
|
Date |
Name |
Title |
Volume |
Trade Price |
Holding Change |
|
5/23/2012
|
CORNELIUS JAMES M
|
Director
|
-5,000
|
$32.48
|
-0.50%
|
|
5/22/2012
|
CORNELIUS JAMES M
|
Director
|
-5,000
|
$32.88
|
-0.50%
|
|
5/18/2012
|
CORNELIUS JAMES M
|
Director
|
-5,000
|
$32.77
|
-0.50%
|
|
5/17/2012
|
CORNELIUS JAMES M
|
Director
|
-5,000
|
$33.00
|
-0.50%
|
|
5/8/2012
|
CORNELIUS JAMES M
|
Director
|
-5,000
|
$33.09
|
-0.49%
|
Data provided by Insiderslab.com. To read detailed Insider Trading Research Report for (BMY), click here.
-
Merck investors are getting paid to wait until top-line trends improve.
Read More »
-
The pharmaceutical giant reported decent first quarter results late in April 2012. However, It will likely be some time before Eli Lilly sees an extended period of steady, sustainable sales growth.
Read More »
-
A possible sale of Amylin might not be such a bad thing.
Read More »
-
These three big drug stocks offer attractive yields and relative safety heading into the more challenging summer months, and risk can be well controlled on all three now.
The health care sector had ...
Read More »
-
Despite all of these uncertainties, investors still heavily focus on whether a company's new drug will be approved by the FDA.
Read More »
Free Reports
|
|
